Carbetocin at elective caesarean section: a sequential allocation trial to determine the minimum effective dose in obese women

T Drew, M Balki, D Farine, X Y Ye, K Downey, J C A Carvalho, T Drew, M Balki, D Farine, X Y Ye, K Downey, J C A Carvalho

Abstract

Postpartum haemorrhage is a leading cause of maternal death during childbirth. There is an increasing incidence of atonic postpartum haemorrhage in developed countries, and maternal obesity has been proposed as a contributing factor. The dose-response relationship of carbetocin in obese women has not yet been determined. We conducted a double-blind, dose-finding study of carbetocin using a biased coin up-and-down design in women with a body mass index ≥ 40 kg.m-2 undergoing elective caesarean section. The determinant for a successful response was satisfactory uterine tone, with no intra-operative need for additional uterotonic drugs. Secondary outcomes included the use of additional uterotonic drugs postoperatively, estimated blood loss and adverse effects of carbetocin administration. Thirty women were recruited to the study. The median (IQR [range]) body mass index was 44.93 (41.5-55.2 [40-66.5]) kg.m-2 . The ED90 of carbetocin was estimated as 62.9 (95%CI 57.0-68.7) μg using the truncated Dixon and Mood method, and 68 (95%CI 52-77) μg using the isotonic regression method. The estimated blood loss was 880 (621-1178 [75-2442]) ml. The overall rates of hypotension and hypertension after delivery were 40% and 6.7%, respectively, while nausea occurred in 26.7% of women. The ED90 for carbetocin in obese women at elective caesarean section is lower than the dose of 100 μg currently recommended by the Society of Obstetricians and Gynaecologists of Canada, but is approximately four times higher than the previously demonstrated ED90 of 14.8 μg in women with body mass index < 40 kg.m-2 .

Trial registration: ClinicalTrials.gov NCT03672045.

Keywords: caesarean section; carbetocin; obesity; postpartum haemorrhage; uterotonic drug.

© 2019 Association of Anaesthetists.

References

    1. AbouZahr C. Global burden of maternal death and disability. British Medical Bulletin 2003; 67: 1-11.
    1. World Health Organization. WHO recommendations. Uterotonics for the prevention of postpartum haemorrhage. 2018. (accessed 29/10/2019).
    1. Gallos ID, Williams HM, Price MJ, et al. Uterotonic agents for preventing postpartum haemorrhage: a network meta-analysis. Cochrane Database of Systematic Reviews 2018; 4: CD011689.
    1. Heesen M, Carvalho B, Carvalho JCA, et al. International consensus statement on the use of uterotonic agents during caesarean section. Anaesthesia 2019; 74: 1305-19.
    1. Lutomski JE, Byrne BM, Devane D, Greene RA. Increasing trends in atonic postpartum haemorrhage in Ireland: an 11-year population-based cohort study. British Journal of Obstetrics and Gynaecology 2012; 119: 306-14.
    1. Joseph KS, Rouleau J, Kramer MS, et al. Investigation of an increase in postpartum haemorrhage in Canada. British Journal of Obstetrics and Gynaecology 2007; 114: 751-9.
    1. Callaghan WM, Kuklina EV, Berg CJ, Trends in postpartum hemorrhage: United States 1994-2006. American Journal of Obstetrics and Gynecology 2010; 202: 353-e1.
    1. Knight M, Callaghan WM, Berg C, et al. Trends in postpartum hemorrhage in high resource countries: a review and recommendations from the International Postpartum Hemorrhage Collaborative Group. BMC Pregnancy and Childbirth 2009; 9: 55.
    1. Mehrabadi A, Liu S, Bartholomew S, et al. Temporal trends in postpartum hemorrhage and severe postpartum hemorrhage in Canada from 2003 to 2010. Journal of Obstetrics and Gynaecology Canada 2014; 36: 21-33.
    1. Hunter DJ, Schulz P, Wassenaar W. Effect of carbetocin, a long-acting oxytocin analog on the postpartum uterus. Clinical Pharmacology and Therapeutics 1992; 52: 60-7.
    1. Atke A, Vilhardt H. Uterotonic activity and myometrial receptor affinity of 1-deamino-1-carba-2-tyrosine(O-methyl)-oxytocin. European Journal of Endocrinology 1987; 115: 155-60.
    1. Voon HY, Suharjono HN, Shafie AA, Bujang MA. Carbetocin versus oxytocin for the prevention of postpartum hemorrhage: A meta-analysis of randomized controlled trials in cesarean deliveries. Taiwanese Journal of Obstetrics and Gynecology 2018; 57: 332-9.
    1. Su LL, Chong YS, Samuel M. Carbetocin for preventing postpartum haemorrhage. Cochrane Database of Systematic Reviews 2012: CD005457.
    1. Pickering K, Gallos ID, Ioannis D, et al. Uterotonic drugs for the prevention of postpartum haemorrhage: a cost effectiveness analysis. PharmacoEconomics-Open 2019; 3: 163-76.
    1. Leduc D, Senikas V, Lalonde AB. Reaffirmed SOGC clinical practice guideline. No. 235-active management of the third stage of labour: prevention and treatment of postpartum hemorrhage. Journal of Obstetrics and Gynaecology of Canada 2018; 40: e841-55.
    1. Boucher M, Horbay GL, Griffin P, et al. Double-blind, randomized comparison of the effect of carbetocin and oxytocin on intraoperative blood loss and uterine tone of patients undergoing cesarean section. Journal of Perinatology 1998; 18: 202-7.
    1. Dansereau J, Joshi AK, Helewa ME, et al. Double-blind comparison of carbetocin versus oxytocin in prevention of uterine atony after cesarean section. American Journal of Obstetrics and Gynecology 1999; 180: 670-6.
    1. Borruto F, Treisser A, Comparetto C. Utilization of carbetocin for prevention of postpartum hemorrhage after cesarean section: a randomized clinical trial. Archives of Gynecology and Obstetrics 2009; 280: 707-12.
    1. Boucher M, Durocher F. Dose ranging study of the effectiveness of carbetocin in producing uterine contraction following delivery of the infant at caesarean section. Data on file at Ferring Inc, 1995.
    1. Khan M, Balki M, Ahmed I, Farine D, Seaward G, Carvalho JC. Carbetocin at elective Cesarean delivery: a sequential allocation trial to determine the minimum effective dose. Canadian Journal of Anesthesia 2014; 61: 242-8.
    1. Monks DT, Palanisamy A. Intrapartum oxytocin: time to focus on longer term consequences. Anaesthesia 2019; 74: 1219-22.
    1. Poston L, Caleyachetty R, Cnattingius S, et al. Preconceptional and maternal obesity: epidemiology and health consequences. Lancet Diabetes and Endocrinology 2016; 4: 1025-36.
    1. Pace NL, Stylianou MP. Advances in and limitations of up-and-down methodology: a precis of clinical use, study design, and dose estimation in anesthesia research. Anesthesiology 2007; 107: 144-52.
    1. Stylianou M, Flournoy N. Dose finding using the biased coin up-and-down design and isotonic regression. Biometrics 2002; 58: 171-7.
    1. Dixon WJ, Mood AM. A method for obtaining and analyzing sensitivity data. Journal of the American Statistical Association 1948; 43: 109-26.
    1. Cordovani D, Balki M, Farine D, Seaward G, Carvalho JC. Carbetocin at elective Cesarean delivery: a randomized controlled trial to determine the effective dose. Canadian Journal of Anesthesia 2012; 59: 751-7.
    1. Anandakrishnan S, Balki M, Farine D, Seaward G, Carvalho JC. Carbetocin at elective Cesarean delivery: a randomized controlled trial to determine the effective dose, part 2. Canadian Journal of Anesthesia 2013; 60: 1054-60.
    1. Tabl S, Balki M, Downey K, et al. Uterotonics in elective caesarean delivery: a randomised non-inferiority study comparing carbetocin 20 μg and 100 μg. Anaesthesia 2019; 74: 190-6.
    1. Carvalho JCA, Balki M, Kingdom J, Windrim R. Oxytocin requirements at elective cesarean delivery: a dose-finding study. Obstetrics and Gynecology 2004; 104: 1005-10.
    1. Fuchs AR, Fuchs F, Husslein P, Soloff MS. Oxytocin receptors in the human uterus during pregnancy and parturition. American Journal of Obstetrics and Gynecology 1984; 150: 734-41.
    1. Moertl MG, Friedrich S, Kraschl J, Wadsack C, Lang U, Schlembach D. Haemodynamic effects of carbetocin and oxytocin given as intravenous bolus on women undergoing caesarean delivery: a randomised trial. British Journal of Obstetrics and Gynaecology 2011; 118: 1349-56.
    1. Rosseland LA, Hauge TH, Grindheim G, Stubhaug A, Langesaeter E. Changes in blood pressure and cardiac output during cesarean delivery: the effects of oxytocin and carbetocin compared with placebo. Anesthesiology 2013; 119: 541-51.
    1. Butwick AJ, Coleman L, Cohen SE, Riley ET, Carvalho B. Minimum effective bolus dose of oxytocin during elective Caesarean delivery. British Journal of Anaesthesia 2010; 104: 338-43.
    1. Nguyen-Lu N, Carvalho JCA, Farine D, Seaward G, Ye XY, Balki M. Carbetocin at Cesarean delivery for labour arrest: a sequential allocation trial to determine the effective dose. Canadian Journal of Anesthesia 2015; 62: 866-74.
    1. Blomberg M. Maternal obesity and risk of postpartum hemorrhage. Obstetrics and Gynecology 2011; 118: 561-8.
    1. Butwick AJ, Abreo A, Bateman BT, et al. Effect of maternal body mass index on postpartum hemorrhage. Anesthesiology 2018; 128: 774-83.
    1. Zhang J, Bricker L, Wray S, Quenby S. Poor uterine contractility in obese women. British Journal of Obstetrics and Gynaecology 2007; 114: 343-8.
    1. Smith RD, Babiychuk EB, Noble K, Draeger A, Wray S. Increased cholesterol decreases uterine activity: functional effects of cholesterol alteration in pregnant rat myometrium. American Journal of Physiology-Cell Physiology 2005; 288: C982-8.
    1. Gimpl G, Fahrenholz F. Human oxytocin receptors in cholesterol-rich vs. cholesterol-poor microdomains of the plasma membrane. European Journal of Biochemistry 2000; 267: 2483-97.
    1. Vricella LK, Louis JM, Chien E, Mercer BM. Blood volume determination in obese and normal- weight gravidas: the hydroxyethyl starch method. American Journal of Obstetrics and Gynecology 2015; 213: 408-e1.

Source: PubMed

Sponsorer og samarbeidspartnere

Medisinsk tilstand

Legemiddelintervensjoner

3
Abonnere